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Management of patients with anorectal melanoma is still controversial. To reach a rationale therapeutic approach, we reviewed our
experience obtained over the past decade. In all, 19 consecutive patients with the diagnosis of anorectal melanoma were included in
this retrospective survey. Details of the patients’ presentation, symptoms, tumour size and histology and tumour state were recorded,
and the primary therapeutic procedures were evaluated in detail. The size of the tumours ranged between 0.5 and 7cm in diameter.
The median tumour thickness was 10mm (range 0.6–40mm). At diagnosis, six of 19 patients already presented with either regional
or distant metastases. The remaining 13 patients were treated with curative intend, either by abdomino-perineal resection (APR) or
wide local excision (WLE). The form of operative therapy, however, had no impact on overall survival. Nevertheless, the incidence of
local recurrences was lower after APR even for patients with less favourable tumours. In conclusion, WLE alone is not sufficient for
local tumour control of thick anorectal melanoma.
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Anorectal melanoma is a rare form of melanoma that constitutes
only 0.4–1.6% of all melanoma manifestations (Wanebo et al,
1981). It accounts only for approximately 0.5% of all colorectal
and anal cancers (Roumen, 1996). Nevertheless, the anorectum is
the most common site for development of primary melanoma in
the alimentary tract. Owing to its low incidence, treatment of
anorectal melanoma to date is not well defined since it was
based on retrospective studies reporting on either a limited
number of cases or data collected over long time periods, that is,
up to 64 years (Brady et al, 1995). Thus, optimal surgical treatment
for primary tumours is still controversial. This is particularly true
if overall survival is not the sole end point, but local tumour
control is also taken into account. The chosen form of therapy
should allow the best possible rehabilitation, that is, a low risk of
local failure and a life free of pain or individual restriction. For
anorectal melanoma, this is the decision between life with a
colostomy after abdomino-perineal resection (APR) or the risk of
local recurrences with severe symptoms after wide local excision
(WLE). Wide local excision is defined as a sphincter saving
procedure with a defined margin around the tumour in two
dimensions; concerning the depth, safety margins are restricted to
the subcutaneous compartment. Thus, the excision is performed
up to the internal sphincter muscle and a side margin to the
tumour up to 2cm.
In this respect, it is important to consider the value of APR.
Although most patients with anorectal melanoma will die from the
disease regardless of the chosen therapeutic strategy, APR may
provide substantial benefits by avoiding severe symptoms caused
by local recurrences, such as incontinence and continuous
bleeding of the tumour, which may require further surgical
interventions. The goal of our study was to evaluate APR and WLE
for management of anorectal melanoma with respect to local
tumour control.
MATERIALS AND METHODS
Between 1992 and 2001, 19 patients with the diagnosis of anorectal
melanoma were treated at the St Josefs Hospital in Wiesbaden, the
Raphaelsklinik in Mu ¨nster and the University Hospital of
Wu ¨rzburg. Patients were considered to have primary melanoma
of the anorectal region when the tumour arose in the rectum, anal
canal or anal margin. Figure 1 depicts the typical macroscopic and
histologic morphology of anorectal melanoma. In the upper right
quadrant of the protological view (arrow), a little pigmented
anoderm is obvious, while the complete papillomatous tumour is
melanoma.
Patients, who’s clinical records showed no clinical evidence of
residual tumour postresection, were interpreted as cured.
Details of the patients’ presentations as well as tumour state, size
and depth were recorded by clinical description and the
histopathologic reports. Follow-up data were obtained for all 19
patients to the point of death or until February 2003 (15–119
months). The use of statistical methods was renounced due
to the limited number of patients in the different sub-
groups.
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lRESULTS
The patient cohort consisted of nine females and 10 males. Mean
age at diagnosis was 62 years (range 33–87 years). Initial
symptoms leading to diagnosis included bleeding (n¼11/58%),
sensations of the presence of a mass (n¼4/21%) or pruritus
(n¼3/16%) (Table 1). For two patients, the melanoma was
discovered upon pathologic review of haemorrhoidectomy.
Of the 19 patients, 14 were dead at the time of evaluation; their
death could be attributed to progression of the neoplastic disease.
Five patients were still alive. The median tumour size was 3.2cm in
diameter (range 0.5–9cm) for the total group. The median tumour
size in patients with resectable disease was 3.1cm in diameter
(range 0.5–5cm). Median tumour thickness was 10mm for the
whole cohort (range 0.6–40mm). Notably, median tumour
thickness in patients with resectable disease undergoing APR
was 17mm (range 10–40mm/n¼5). This was compared to a
tumour thickness of 8.5mm (range 0.6–10mm/n¼8) in patients
treated by WLE. Treatment and survival according to tumour
depth is summarised in (Table 3).
At the time of diagnosis, six patients already suffered from
clinically evident metastatic disease (Table 4). All but one of these
patients died within 14 months (mean survival 9 months). The
exception was a 56-year-old man, who survived 38 months after
local excision with liver and renal metastasis. In three of these
stage IV patients, it was necessary to place a palliative stoma to
control complications caused by local tumour growth and
bleeding.
The 13 patients, treated with curative intent could be divided
into two groups: five patients undergoing an APR and eight
patients treated by WLE. Of the five patients treated by APR, two
died after 17 months, the third after 19 months; the fourth patient
had a tumour recurrence in the pelvis after 38 months, which was
treated by resection. He died from tumour progression 23 months
later. The fifth patient remained tumour free for 24 months after
APR.
Figure 1 (A) A 57-year-old women with a polypoid anal melanoma at
31 with little pigment at the base of the polypoid tumour (arrow). (B) Low-
power view of polypoid MM of the anorectal region with superficial
ulceration (HE  80). (C) Detail: Extensive tumour growth beneath intact
surface squamous epithelium (HE  250). Table 3 Treatment and survival according to tumour depth
Depth
(mm) Number
Local
excision APR Palliative
Median survival
(months)
0–1 1 1 (alive) 119
1–4 1 1 (alive) 51
4–10 8 5 (two alive) 1 (one alive) 2 20
10–20 7 1 3 3 23
420 2 1 1 12
APR¼abdomino-perineal resection.
Table 2 Recurrence distribution after curative treatment
Localisation No. of patients
a
Liver 4
Lung 4
Pelvic 1
Local plus systemic 1
Isolated local 4
Inguinal lymph node 1
aSome patient may have recurrence at more than one site.
Table 1 Symptoms at first presentation, n¼19
Symptom No. of patients (%)
Rectal bleeding 11 (58)
Pruritus 4 (21)
Mass 3 (16)
Anal pain 2 (10)
Inguinal mass 2 (10)
Meteorism 2 (10)
Incontinence 1 (5)
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lOf the eight patients treated by WLE, one died after 8 months
with systemic tumour recurrence. Five patients (62.5%) presented
themselves with local recurrences; in three of them it was detected
in an early state without any clinical symptoms, but two suffered
from massive tumour growth with persistent bleeding. Three of
these patients were treated by APR; in two patients a second WLE
was performed. Of the latter, one needed a palliative stoma due to
incontinence and he died within 9 months; the other patient was a
59-year-old women, who presented with local tumour recurrence
after 36 months, but she did not develop any additional recurrence
in the subsequent follow up of 83 months.
Eight of the 13 patients with resectable disease died from disease
progression at a mean of 25 months (range 14–61 months) (Table 2).
Five patients were still alive and tumour free (mean follow-up of 33
months (range 15–119 months) at the evaluation date.
It was not possible to make a statistical statement about long-
term survival due to the limited number of patients.
DISCUSSION
The prognosis of anorectal melanoma as for most other mucosal
presentations of melanoma is poor (Chung et al, 1980; Kato et al,
1987; Going et al, 1989). This poor prognosis seems to be due to
the late detection of the disease. Symptomatic tumours are
normally large in size and show a deep penetration. Thus, up to
one-third of the patients already suffer from dissemination at the
time of diagnosis (16–33%) (Thibault et al, 1997). This notion
reflects our own observations with 32% of the patients suffering
from metastatic disease at the time of diagnosis. For these patients
there is currently no established therapeutic approach, which
allows a favourable outcome.
With regard to patients undergoing surgery with a curative
intent, our study further confirms the poor prognosis reported
from previous series. Currently, there is no firm recommendation
towards either conservative, that is, WLE, or radical, that is APR,
surgical approaches. Meta-analyses with the compiled data of 426
patients failed to show the advantage of either approach with
respect to overall survival (Thibault et al, 1997). It should be noted,
however, that in most studies it is difficult to compare patient’s
prognostic factors due to the fact that insufficient information is
provided. Nevertheless, there was a trend that local disease is more
effectively controlled by APR than WLE (Abbas et al, 1980; Ross
et al, 1990; Roumen, 1996; Thibault et al, 1997). To this end,
Thibault reported that isolated local recurrences after APR were
rare (Thibault et al, 1997). In all, 10 long-term survivors were
reported by Brady in a cohort of 85 patients; nine of them received
an APR; thus, advocating APR (Brady et al, 1995). The mean
tumour depth in patients with resectable disease undergoing APR
was 7.5mm (range 0.5–20) compared with 6mm (range 4–9) in
the group of patients treated with local procedures. However, this
study is flawed by several inconsistencies such as missing progress
reports or the fact that none of the locally treated tumours were
below 4mm in tumour thickness. Roumen (1996) reported a series
of 34 patients, 18 of them were treated by APR whereas 16 patients
received WLE. Interestingly, only one of the patients treated by
APR developed a local recurrence. In contrast, local recurrences
were observed in most of the patients (12 of 16) who underwent
WLE. Seven of these 12 patients also presented a systemic
recurrence. Unfortunately, only for 60% of the patients the
histological tumour thickness was given. Ballo et al (2002)
reported that adjuvant radiation of the pelvis and inguinal lymph
nodes after WLE showed similar rates of local tumour control as
APR. From 23 patients with mean histological tumour thickness of
5mm (range 0.3–35mm), five of them had a local and three a
nodal failure, but none of these patients required an APR for
palliation.
Anorectal melanoma may represent a systemic disease at the
time of diagnosis in most cases, and the choice of the surgical or
other local procedures to amend the primary tumour has no
influence on the systemic course of the disease.
Thus, therapeutic strategies should be adjusted to the prognosis
of the disease. Unfortunately, prognostic parameters for anorectal
melanoma remain to be defined. Only a few studies addressed this
pertinent question. Goldman et al (1990) reported a correlation
between overall survival and the size of the tumour. Among 33
evaluated patients only two were long-term survivors. These two
patients were characteriszed by a tumour size of less than 2cm in
diameter. The tumour thickness was below 2.5mm. Unfortunately,
in this study the histopathologic data were not reported for all
patients.
In contrast, Slingluff et al (1990) suggested that the only
predictive factor for survival was stage of disease, that is, local,
regional or systemic, at the time of diagnosis, whereas Ballo et al
(2002) reported a favourable disease-free survival outcome when
the tumour thickness was below 4mm.
Hence, anorectal melanoma seems to be similar to cutaneous
melanoma for which stage of disease and tumour thickness are the
main prognostic factors. For cutaneous melanoma these factors are
considered essential to plan further therapeutic procedures. If
anorectal melanoma – maybe only anal melanoma – is in this
respect indeed comparable to cutaneous melanoma, it should be
handled accordingly; thus, the decision between WLE and APR
should be governed by the tumour thickness. Preoperative
measurement of the tumour thickness may prove to be a valuable
tool to plan the operation.
The aim for surgical therapy of anorectal melanoma is to
maximise quantity and quality of life. Based on this aim, in early
disease with a tumour thickness below 1mm, a local sphincter
saving excision with 1cm safety margin would be appropriate. In
the cases of a tumour thickness between 1 and 4mm, a local
sphincter saving excision with a safety margin of 2cm seems to be
adequate, if the internal sphincter muscle is not afflicted. With
respect to local tumour control, WLE alone does not seem to be
adequate treatment for anorectal melanomas with a tumour
thickness above 4mm. These patients would benefit from an
APR or additional measures to control local tumour reoccurrences
in combination with a WLE. If such patients decide to have only a
WLE, they should be aware that local failure is common and
complications requiring additional surgery may occur. In this
respect, adjuvant radiation has been suggested to hold the promise
of sphincter preservation together with sufficient tumour control
(Ballo et al, 2002). However, acute radiation-related dermatitis was
noted by most patients and chronic radiation-related toxicity
occurred in six of 23 patients.
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Table 4 Tumour depth according to filiae at diagnosis
No. Depth (mm) Location
1 6 Inguinal lymph node
2 10 Inguinal lymph node
3 11 Liver
4 12 Inguinal lymph node
5 40 Lung, inguinal lymph node
6 20 Liver, kidney
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